{"analyses":[{"ciLowerLimit":"-13.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-1.67","groupDescription":"Creatinine clearance, baseline versus end study levels.","groupIds":["OG000"],"nonInferiorityComment":"P-values and confidence intervals are not adjusted for multiple testing","nonInferiorityType":"OTHER","pValue":"0.017","paramType":"Change in outcome measure","paramValue":"-7.39","statisticalComment":"degrees of freedom = 10","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.0","value":"82.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Creatinine clearance (ml/min) and proteinuria (g/day) were assessed at baseline, 6 and 12 months, with change at change at end of study reported","dispersionType":"Standard Deviation","groups":[{"description":"Patients with predominant amyloid kidney involvement at enrollment.","id":"OG000","title":"Amyloid Nephropathy"}],"paramType":"MEAN","populationDescription":"Analysis is limited to the patients with predominant amyloid kidney involvement at enrollment. Mixed models analyses of change from baseline levels of creatinine clearance (ml/min) and proteinuria (g/day) were performed to include all collected data.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Amyloid Nephropathy: Creatinine Clearance","type":"PRIMARY","unitOfMeasure":"ml/min"}